ARCHIVES

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

In Brief: Benjamin Neel named director of NYU Cancer Center

October 24, 2014

Studies Question PSA Screening: PLCO Trial Finds No Survival Advantage, European Trial Finds Benefit At High Cost

March 20, 2009

FDA Advisors Uphold Broad Mandate To Limit Use Of ESA Products In Cancer Indications.

May 11, 2007

Emil Frei, Pioneer of Combination Chemotherapy, Dies at 89

May 10, 2013

Phase III Trial Demonstrates Early Docetaxel Combined With ADT Can Extend Survival

December 27, 2013

Price Increase

July 22, 1983